The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.

Origami is collaborating with Ipsen to develop molecules designed to remove or correct abnormal proteins in neurodegenerative diseases.

A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, aimed at improving access to quality medical ...

Scientists developed a technique to grow cells that control voluntary movement, a discovery that could aid ALS and spinal ...

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166 ...

Some weights weren't getting any use until columnist Dagmar Munn applied one of her "imaginary rules" toward a lesson in ...

A viral infection can trigger a neurological disease similar to amyotrophic lateral sclerosis (ALS) in mice with a specific ...

A new survey suggests many people with ALS would value even modest slowing of ALS progression as a treatment goal.

Coya Therapeutics raised $11.1 million to support manufacturing scale-up for its experimental ALS therapy, COYA 302.

Watching dancers capture both grief and joy reminded columnist Kristin Neva of her own life as a caregiver to her husband, who has ALS.

Reducing RAD23A levels helped nerve cells better handle toxic TDP-43 protein clumps, improving survival and function in an ALS mouse model.

After 15 years with her husband's ALS, columnist Kristin Neva recognizes that it's still possible to find comfort, even without solutions.